BOSTON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and...
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that its Biologics License Application (BLA) for...
ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2022 annual report (ESEF-version ALK-2022-12-31-en...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing...
TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage...
On Friday, 3 February 2023 expectedly around noon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report...
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing...
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents...
TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA),...
Mount Sinai’s Dr. Nina Bhardwaj and Cell BioEngines Founder and CEO Dr. Ajay Vishwakarma Mount Sinai’s Dr. Nina Bhardwaj and...
WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused...
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical...
Dr. Dirbas, Associate Professor of Surgery at the Stanford School of Medicine will chair the Scientific Advisory Board (SAB) The...
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK,...
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated...
CancerVAX CEO Ryan Davies speaks with Todd Kinard, a leading biotech intellectual property (IP) expert about how patents can be...